RHS Ltd. said it implemented a previously announced scheme of arrangement to be acquired by Waltham, Mass.-based PerkinElmer Inc.

The scheme was approved by RHS' shareholders and the Federal Court of Australia in May 22 and May 29, respectively. All RHS options were transferred to PerkinElmer and were canceled following the implementation of the scheme, the company said in a news release.

The scheme's consideration of 28 Australian cents per share will be issued to RHS shareholders who held RHS shares on the record date of June 6.

Meanwhile, David Brookes, Johnathon Matthews, Sue MacLeman and Colin Matthews stepped down from the RHS board of directors following the scheme's implementation. Ray Ridge also resigned as company secretary.

The Australia-based biotechnology company also appointed John Healy, Daisy Yan and Oksana Mugalimova to serve as directors of the company, while Mugalimova was also appointed company secretary to fill the vacated positions.